Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Publication year range
1.
J Med Vasc ; 47(4): 186-190, 2022 Oct.
Article in English | MEDLINE | ID: mdl-36344029

ABSTRACT

Lipodermatosclerosis or sclerotic hypodermitis is presented as a complication of venous insufficiency and in particular of post-thrombotic syndrome with a high risk of progression to leg ulcers. However, it has also been described in obese patients without venous insufficiency, and even in the course of various systemic diseases including scleroderma. It most often affects middle-aged women and is usually bilateral, with a typically "inverted champagne bottle" leg appearance. The pathogenic role of venous hypertension explains why compression with bands or stockings is the basis of treatment. In acute phase, which may precede or complicate chronic forms, the pain is so severe that compression is not tolerated. In acute phase, non-steroidal anti-inflammatory drugs, intra-lesional use of triamcinolone, and capsaicin transdermal patches indicated for neuropathic pain have been proposed. In chronic forms, the treatment of superficial venous insufficiency and/or incontinent perforating veins, documented during a Duplex ultrasound scan, is usually proposed, whenever possible. In association with elastic compression, pentoxifylline and colchicine have been used without clear evidence of clinical efficacy. Finally, in the most advanced clinical presentation with the appearance of a sclerotic gaiter associated with ulcerations, surgical treatment with excision-cutaneous grafting associated or not with perforating veins ligation and a fasciotomy may be discussed as a last resort for treatment.


Subject(s)
Dermatitis , Postthrombotic Syndrome , Scleroderma, Localized , Venous Insufficiency , Middle Aged , Humans , Female , Scleroderma, Localized/complications , Scleroderma, Localized/therapy , Venous Insufficiency/diagnostic imaging , Venous Insufficiency/etiology , Venous Insufficiency/therapy , Dermatitis/complications , Postthrombotic Syndrome/complications
3.
J Med Vasc ; 45(4): 175-176, 2020 07.
Article in English | MEDLINE | ID: mdl-32571556
5.
Ann Dermatol Venereol ; 145(12): 761-764, 2018 Dec.
Article in French | MEDLINE | ID: mdl-30197053

ABSTRACT

BACKGROUND: Digital necrosis is rarer than lower limb necrosis and constitutes a medical or surgical emergency. Etiological evaluation is required. Cold agglutinin disease is a cause of digital necrosis but diagnosis is difficult. PATIENTS AND METHODS: Herein we report the case of a 57-year-old man presenting recent paroxysmal acrosyndrome of the left hand subsequently complicated by digital necrosis following occupational exposure to cold in his work as a forklift driver. After etiological evaluation, a diagnosis of primary cold agglutinin disease was made. Intravenous rituximab and topical treatment resulted in complete healing. DISCUSSION: Cold agglutinin disease is a rare type of auto-immune hemolytic anemia. Following exposure to cold, paroxysmal cutaneous signs are frequent. The disease may be either primary or secondary with B-cell lymphoproliferative disorder, auto-immune disease or infection. A thorough workup is required. To date, the treatment combining the best positive response rate and good safety is rituximab in weekly perfusions over a 1-month period.


Subject(s)
Anemia, Hemolytic, Autoimmune/diagnosis , Fingers/pathology , Hand Deformities, Acquired/etiology , Immunosuppressive Agents/therapeutic use , Ischemia/etiology , Raynaud Disease/etiology , Rituximab/therapeutic use , Amputation, Surgical , Anemia, Hemolytic, Autoimmune/complications , Anemia, Hemolytic, Autoimmune/drug therapy , Anemia, Hemolytic, Autoimmune/surgery , Cold Temperature , Combined Modality Therapy , Computed Tomography Angiography , Cryoglobulins/analysis , Fingers/blood supply , Fingers/diagnostic imaging , Fingers/surgery , Humans , Immunoglobulin kappa-Chains/blood , Ischemia/surgery , Male , Middle Aged , Necrosis , Occupational Diseases/etiology , Raynaud Disease/diagnostic imaging , Smoking/adverse effects
6.
J Eur Acad Dermatol Venereol ; 32(3): 437-440, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29055135

ABSTRACT

BACKGROUND: Prurigo is a common primary pruritic condition. Treatment is challenging. Methotrexate (MTX) is effective for the treatment of pruriginous dermatoses, but its use in prurigo has been little studied. OBJECTIVES: To investigate the efficacy and safety of MTX in the treatment of difficult-to-treat prurigo. METHODS: Patients from six university dermatology departments treated with MTX between 2006 and 2016 for difficult-to-treat prurigo (i.e. with failure to conventional therapies) were included in this retrospective multicentre study. Patients with other pruritic dermatoses were excluded. Clinical efficacy was recorded after 3, 6 and 12 months of treatment: (i) subjective efficacy, that is, evaluation of the pruritus by the patient and (ii) objective efficacy, that is, assessment of cutaneous lesions by the physician: complete or almost complete remission (CR) (healing of lesions), partial remission (PR) (incomplete improvement of lesions) or failure (no improvement or worsening). The overall response rate (ORR) included CR and PR. RESULTS: Thirty-nine patients with previous failure of topical steroids, H1-antihistamine drugs or phototherapy were included. The median weekly dose of MTX was 15 mg (range 5-25 mg). The median follow-up was 16 months (2-108). The mean time between onset of MTX and objective efficacy was 2.4 ± 1.2 months and the mean duration of response was 19 ± 15 months. The ORR was 91% at 3 months [n = 36, CI 95% (81.2-100.8%), CR 44%], 94% at 6 months [n = 32, CI 95% (85.7-102.2%), CR 56%] and 89% at 12 months [n = 28, CI 95% (77.4-100.6%), CR 57%]. Seven patients stopped MTX because of failure, and five because of the discovery of hepatocarcinoma (n = 1), elevated transaminases (n = 1), infectious pneumonitis (n = 1) or gastrointestinal symptoms (n = 2). CONCLUSION: Methotrexate is a therapeutic option in difficult-to-treat prurigo.


Subject(s)
Dermatologic Agents/therapeutic use , Folic Acid Antagonists/therapeutic use , Methotrexate/therapeutic use , Prurigo/drug therapy , Adult , Aged , Aged, 80 and over , Chronic Disease , Female , Humans , Male , Middle Aged , Remission Induction , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...